Get the Stockscreener App
930.66
0.52%
3.60
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $930.66, with a volume of 1.64M.
It is up +0.52% in the last 24 hours and down -5.90% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$927.06
Open:
$924.5
24h Volume:
1.64M
Relative Volume:
0.52
Market Cap:
$832.53B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
41.20
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
+1.32%
1M Performance:
-5.90%
6M Performance:
+10.47%
1Y Performance:
+28.77%
1-Day Range:
$898.45
$932.64
1-Week Range:
$898.45
$976.68
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
931.91 | 828.20B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.60 | 580.40B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
205.24 | 365.59B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
200.79 | 314.56B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
118.19 | 298.79B | 64.93B | 18.26B | 12.36B | 7.2751 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Is Eli Lilly Stock a Buy After a Brand New Approval? - Yahoo Finance
Eli Lilly Stock Is Down 13% in 2026. Does Foundayo Change the Math? - TIKR.com
Lexaria Eyes Growing Oral GLP-1 Market After Eli Lilly’s Foundayo Approval - TipRanks
Eli Lilly (LLY) Gains FDA Approval for New Obesity Treatment - GuruFocus
Eli Lilly (LLY) Stock Dips Following FDA Approval of Foundayo Oral Weight-Loss Drug - Blockonomi
AC Immune, Lilly Amend Morphomer Tau Alliance - Contract Pharma
Eli Lilly (LLY) Stock: FDA Greenlights Foundayo as GLP-1 Market Expansion Accelerates - CoinCentral
Lexaria Applauds Eli Lilly's Foundayo Drug Approval - Investing News Network
FDA approves Eli Lilly’s oral weight-loss tablet Foundayo - Investing.com
Novo Nordisk (NVO.US) Prices High-Dose Wegovy at USD399 per Month, Below Eli Lilly (LLY.US) Zepbound - AASTOCKS.com
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval - The Joplin Globe
A third oral GLP-1 wins FDA approval, and Lexaria sees an opening - Stock Titan
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know - Yahoo Finance
AI Models Diverge on Eli Lilly: Premium Growth or Priced for Perfection? - TipRanks
Lilly’s Foundayo approved by US FDA as oral GLP-1 for weight loss - PMLiVE
AC Immune amends Lilly collaboration, plans tau drug studies By Investing.com - Investing.com India
Novo Undercuts Lilly With High-Dose Wegovy at $399 a Month - Bloomberg.com
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - 富途牛牛
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly - Yahoo Finance UK
Thurston Springer Miller Herd & Titak Inc. Buys 7,055 Shares of Eli Lilly and Company $LLY - MarketBeat
Toth Financial Advisory Corp Acquires 1,082 Shares of Eli Lilly and Company $LLY - MarketBeat
Analyst Boosts Eli Lilly Stock Holdings - National Today
Eli Lilly and Company (LLY) Price Target Raised Following FDA Approval for Fundayo - Insider Monkey
Eli Lilly to buy Centessa Pharmaceuticals for initial $6.3 billion - MSN
Wegovy beats Foundayo in Novo Nordisk weight loss study - qz.com
Eli Lilly's Strategic Pivot: Building a Neuroscience Division Through Major Acquisition - AD HOC NEWS
Eli Lilly and Company (NYSE:LLY) Stock Price Down 1% on Analyst Downgrade - marketbeat.com
Eli Lilly and Co.’s Foundayo: New FDA-approved oral weight loss medication - WISH-TV
FDA Approves Eli Lilly GLP-1 Pill for Weight Loss - Mix93.3
Trump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a Dime - Investing.com
New GLP-1 drug will be made in Houston - KHOU
How to Play Lilly Stock Post Oral Obesity Pill Foundayo's Approval - Yahoo Finance
Novo Nordisk says its Wegovy pill beats Eli Lilly's rival on weight loss - qz.com
Lilly vs JPMorgan: Which Hits a $1 Trillion Market Cap First? - 247wallst.com
Eli Lilly’s Path to $1 Trillion Runs Directly Through the AI Boom - AOL.com
Eli Lilly takes the court with 150th anniversary campaign to catch Final Four crowd - Fierce Pharma
Eli Lilly & Co. stock: Foundayo approval drives gains – what it means for you - AD HOC NEWS
Eli Lilly's $6.5B Houston plant will make its new FDA-approved GLP-1 weight loss drug - bizjournals.com
Evexia Wealth LLC Sells 1,147 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY is Aberdeen Group plc's 10th Largest Position - MarketBeat
Eli Lilly and Company (NYSE:LLY) Stock Rating Lowered by Wall Street Zen - MarketBeat
Eli Lilly's Foundayo Launch and Strategic Acquisition Signal Aggressive Growth - AD HOC NEWS
StockWatch: Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod - Genetic Engineering and Biotechnology News
Oral Weight-Loss Drug Battle: Novo Nordisk vs Eli Lilly's New TreatmentsNews and Statistics - indexbox.io
AI Models Split on Eli Lilly (LLY) as Growth Strength Meets Premium Valuation - TipRanks
HF Advisory Group LLC Boosts Stake in Eli Lilly and Company $LLY - MarketBeat
SWS Partners Makes New $2.39 Million Investment in Eli Lilly and Company $LLY - MarketBeat
Herbst Group LLC Makes New Investment in Eli Lilly and Company $LLY - MarketBeat
Banque Pictet & Cie SA Cuts Holdings in Eli Lilly and Company $LLY - MarketBeat
Beacon Investment Advisory Services Inc. Sells 1,080 Shares of Eli Lilly and Company $LLY - MarketBeat
Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be a Blockbuster” - Insider Monkey
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):